Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$8.2 million.

  • InMed Pharmaceuticals' Net Income towards Common Stockholders fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.34% down from last year.
  • As of FY2025, InMed Pharmaceuticals' Net Income towards Common Stockholders stood at -$8.2 million, which was down 6.34% from -$7.7 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$7.7 million for FY2024, and its period low was -$18.6 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$7.9 million, with a median of -$7.9 million in 2023.
  • In the last 5 years, InMed Pharmaceuticals' Net Income towards Common Stockholders spiked by 57.27% in 2023 and then declined by 6.34% in 2025.
  • InMed Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$18.6 million in 2022, then surged by 57.27% to -$7.9 million in 2023, then grew by 3.42% to -$7.7 million in 2024, then dropped by 6.34% to -$8.2 million in 2025.